Sequana Medical
Health & Medical Electronics
Startup · Series CNo open roles listed
$25.8MTotal raised
Facts
as of Nov 21, 2026Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer.
- Founded
- 2018
- Employees
- 501-1000estimated range
- Official records
- Wikidata Q115167120LEI 8755009AN12Y4PEOII07
- Website
- sequanamedical.com
These are the key facts about Sequana Medical on Alion as of Nov 21, 2026. It was founded in 2018. The latest round is Series C of $25.8M, announced in 2014.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 1 record →Sequana Medical has $25.8M paid in by investors, lenders and donors.
$25.8MPaid in
Money innewest first
$25.8MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Ownership
All holders and entities →Sources name BioMedInvest, Capricorn Venture Partners, Entrepreneurs Fund among the owners or investors of Sequana Medical.
Named investors, no share stated5
Holders and shares as each register or filing states them.
Products
Products →Sequana Medical paid US doctors and teaching hospitals $8.5k in 2025, and $286k for research (CMS Open Payments).
FDA approvals
alfapump System
Device approval (PMA) · P230044 · alfapump System · Gastroenterology, Urology
Dec 2024
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →Sequana Medical: 6 research papers in five years.
No match
None
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Jul 11, 2018
Founded
2018
Apr 15, 2015
Raised a round Series C $25.8M · led by Life Science Partners · PE Hub
Apr 28, 2014
Sources: the outlets named on each headline, each story once
